Phaseline

Targets › STEAP2

STEAP2 (Metalloreductase STEAP2): drug programs, companies and trials

3 programs from 2 companies in 3 trials: 3 Phase 1; Oncology; next expected readout Jan 2027.

Integral membrane protein that functions as a NADPH-dependent ferric-chelate reductase, using NADPH from one side of the membrane to reduce a Fe(3+) chelate that is bound on the other side of the membrane (By similarity). Mediates sequential transmembrane electron transfer from NADPH to FAD and onto heme, and finally to the Fe(3+) chelate (By similarity). (UniProt, Q8NFT2)

Open in Phaseline: the race on STEAP2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai AbelZetaA-CAR032
dnTGFβRII-armoured STEAP2-targeted CAR T cell therapy
STEAP2Phase 1Prostate CancerJan 2027
AstraZenecaAZD8359
STEAP2-targeting T cell engager (TCE)
STEAP2Phase 1Metastatic Prostate CancerNov 2027
AstraZenecaAZD6621
T cell-engaging antibody targeting STEAP2, CD3, and CD8
STEAP2, CD3, CD8Phase 1Prostate CancerMar 2029

Conditions

Prostate Cancer (2) Metastatic Prostate Cancer (1)

Modalities

small molecule (2), other (1)

Companies

AstraZeneca (2) Shanghai AbelZeta (1)

Related targets

CD3 (1) CD8 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.